Skip to main content
Premium Trial:

Request an Annual Quote

Susan Forsburg, Richard Lerner, J. Stark Thompson, Lou Lavigne, David Ebersman

Eugene Bauer, professor emeritus and former dean of the Stanford University School of Medicine, joins Neosil as CEO, the company said this week. Clarence Dellio, former COO at Xoma, was named president and COO. Prior to Xoma, Dellio was vice president, manufacturing, for Becton Dickinson. Additionally, Neosil named Bauer to its newly formed board of directors, which includes Nicholas Simon III, general partner, MPM Capital; Ashley Dombkowski, principal, MPM Capital; Ann Hanham, managing director, Burrill & Co.; and Teddy Shalon, managing director, Shalon Ventures.


Gloria Lee joined Cougar Biotechnology of Los Angeles as vice president of clinical research and development. Lee joined Cougar from Chiron, where she was senior director for clinical development in oncology since 2003. Previously she held clinical development positions at Rhone Poulenc Rorer (now Aventis) from 1994 through 1999.


Susan Forsburg, associate professor of molecular biology at the University of Southern California and formerly of the Salk Institute for Biological Studies in San Diego, was named a fellow of AAAS, the school said this week. Forsburg was name for her work in “developing and disseminating pioneering tools related to the use of S. pombe fission yeast in fundamental studies of replication of DNA and chromosome dynamics,” AAAS said in a statement.


Pratik Shah joined Thomas, McNerney & Partners of San Francisco as a new venture partner, the firm said this week. Pratik was most recently the chief business officer and co-founder of Kalypsys, a San Diego biotech company. Previously, Pratik was at McKinsey & Co. where he focused on biotechnology and venture capital projects. Thomas, McNerney & Partners is a private equity firm that invests in life science and medical technology companies.


Richard Lerner, president of the Scripps Research Institute, will be the keynote speaker of the 2005 Florida Venture Capital Conference, conference organizer Florida Venture Forum announced this week. The conference will be held Jan. 27-28 in Orlando, Fla.


James Sharpe joined Oragenics of Alachua, Fla., as vice president of business development. Sharpe previously ran Ankyr Consulting, a Princeton, NJ, strategic consulting firm for healthcare and biotechnology companies. Prior to that, he was chief operating officer of FEI Technologies (later named Enhance Pharmaceuticals), which was subsequently sold to Barr Laboratories. He has served as president of Small Molecule Therapeutics.


Peter Lee will join UniServices as chief executive, according to news reports. UniServices is the commercial arm of Auckland University of New Zealand. Lee Previously was chief executive of AgriGenesis, a subsidiary of Genesis.


J. Stark Thompson was elected non-executive chairman of the board of directors of Gene Logic, the Gaithersburg, Md.-based company said this week. Thomas has been a member of the company's board since February 2002. The election comes as the company separates the roles of chairman and chief executive officer. Thompson previously was president and CEO of Life Technologies from 1988 until his retirement in 2000.


Genentech said Wednesday that CFO Lou Lavigne plans to retire in March 2005, and will be succeeded by David Ebersman, currently senior vice president of product operations.

 

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.